Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6646143 | 0.81 | LTA4H (0.51) | LTA4HPTGS1PTGS2PKMHRH3 | |
| SCHEMBL76423 | 0.81 | KMT2A (0.64) | LTA4HALDH1A1KDM4ELMNA | |
| SCHEMBL6228523 | 0.80 | MAPT (0.65) | LTA4HPTGS1PTGS2HRH3ALDH1A1 | |
| SCHEMBL9570575 | 0.79 | DRD2 (0.65) | LTA4HPTGS1PTGS2HRH3ALDH1A1 | |
| SCHEMBL17323481 | 0.78 | ALDH1A1 (0.48) | PKMALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL5286113 | 0.78 | DRD2 (0.73) | PKMALDH1A1DRD2DRD4DRD3 | |
| SCHEMBL10556391 | 0.77 | HRH3 (0.69) | HRH3ALDH1A1DRD2DRD4DRD3 | |
| SCHEMBL10554981 | 0.77 | HRH3 (0.69) | HRH3ALDH1A1DRD2DRD4DRD3 | |
| SCHEMBL9570561 | 0.77 | HRH3 (0.69) | HRH3ALDH1A1DRD2DRD4DRD3 | |
| SCHEMBL10559291 | 0.77 | HRH3 (0.69) | HRH3ALDH1A1DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106795154-B | Isoquinolinone derivatives for treating cancer | 皮埃尔法布雷医药公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-106795154-A | For the isoquinolinone derivatives for the treatment of cancer | 皮埃尔法布雷医药公司 | 2017-05-31 | — | — | CN | disclosed |
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | LTA4H 3511/4885PTGS1 2719/4885PTGS2 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.